Metraipolis › archive › dc_80803c87f77c
ESG performance, financing constraints, and workplace health investment: evidence from Chinese biopharmaceutical enterprises — Europe PMC PMID:41878110
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41878110
- DOI
- 10.3389/fpubh.2026.1765422
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-05T00:28:31.813Z
- SHA-256 of the archived text
d6e66e1fe3130fce07fe076d87338a33efb9a79f092731997a3b0d10f1bbddc0- Stable URL of this page
https://metraipolis.com/documento/dc_80803c87f77c
How to cite
ESG performance, financing constraints, and workplace health investment: evidence from Chinese biopharmaceutical enterprises — Europe PMC PMID:41878110 — Europe PMC (en), https://europepmc.org/article/MED/41878110 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_80803c87f77c (Metraipolis archive dc_80803c87f77c, sha256 d6e66e1fe3130fce07fe076d87338a33efb9a79f092731997a3b0d10f1bbddc0)
BibTeX
@misc{dc80803c87f77c,
title = {ESG performance, financing constraints, and workplace health investment: evidence from Chinese biopharmaceutical enterprises — Europe PMC PMID:41878110},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41878110},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_80803c87f77c; sha256 d6e66e1fe3130fce07fe076d87338a33efb9a79f092731997a3b0d10f1bbddc0},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41878110. Agents can read the archived copy with the MCP tool read_document.